FDA
label_change
· 2022-04-05
FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)
Summary
FDA approved a supplemental application for IBSRELA (tenapanor hydrochloride) submitted by Ardelyx, updating the drug labeling.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for IBSRELA (TENAPANOR HYDROCHLORIDE)